FNP Obesity and Weight Management Questions

Rheumatoid arthritis is a systemic inflammatory disease that frequently presents with constitutional symptoms such as severe fatigue, low-grade fever, and unintended weight loss, alongside symmetric polyarthritis. The combination of systemic symptoms and symmetric wrist swelling strongly indicates an inflammatory autoimmune process. Primary osteoarthritis is a localized mechanical disease that does not cause systemic weight loss or severe fatigue. Fibromyalgia syndrome causes widespread musculoskeletal pain and fatigue but does not produce objective joint swelling. Polymyalgia rheumatica causes proximal muscle stiffness in the shoulders and hips, rather than distal joint swelling in the wrists and ankles.

This patient exhibits systemic symptoms like weight loss and fatigue alongside symmetrical wrist involvement, pointing toward a systemic inflammatory process like rheumatoid arthritis. Finding subcutaneous rheumatoid nodules on the extensor surfaces would further support this primary diagnosis. Option A, Option B, and Option D are classic clinical manifestations of osteoarthritis, which is a localized, non-inflammatory disease that lacks constitutional systemic symptoms and typically features hard bony nodes rather than soft subcutaneous nodules.

Significant weight loss directly reduces the severity of OSA by decreasing pharyngeal tissue burden. Because his airway resistance is now lower, his historical CPAP pressure is too high, causing him to swallow air and wake up frequently. Decreasing the pressure setting empirically is the most direct and appropriate APRN action to resolve over-titration. Ordering an overnight sleep study is unnecessary when a simple clinical adjustment can be trialed first. A chin strap or an auto-titrating device does not immediately address the established problem of excessive fixed pressure.

Clinical guidelines support bariatric surgery referral for patients with a BMI over 35 who have obesity-related comorbidities, such as type 2 diabetes, especially when lifestyle modifications have failed. Option B is incorrect because phentermine is only approved for short-term use, not long-term management. Option C is inappropriate because she has already failed a comprehensive lifestyle approach, and delaying further intervention increases her metabolic risk. Option D is incorrect as liquid fasting protocols require specialized monitoring and are not the standard evidence-based next step for this patient's profile.

The patient's complaint of aching gums combined with significant weight loss strongly points to poor dentition or ill-fitting prosthetics as the root cause of her decreased oral intake. Inquiring about denture fit directly addresses this mechanical barrier to eating. Option A is useful for assessing gastrointestinal motility but does not correlate with her specific localized oral pain. Option B addresses a social determinant of health, but her avoidance of provided senior center lunches suggests the issue is not access to food, but rather the ability to eat it comfortably. Option C investigates pharmacological side effects, which are common, but ignores the explicit cue regarding her oral discomfort.

This patient returns for a 6-month follow-up with worsening hypertension at 158/98 mmHg despite strict adherence to lifestyle modifications. The sudden development of muscle cramps and severe weakness in the setting of resistant hypertension is a classic presentation of hypokalemia, which strongly suggests primary aldosteronism. Evaluating serum potassium and aldosterone levels is the most critical next step to rule out this secondary cause. Adding a thiazide diuretic would be dangerous, as it could exacerbate her underlying hypokalemia and worsen her muscular symptoms. Recommending increased dietary potassium intake fails to investigate the root cause of her new, concerning symptoms and delays necessary diagnostic workup. Prescribing an angiotensin receptor blocker might lower her blood pressure but completely ignores the clinical signs pointing toward a potentially curable endocrine cause of her secondary hypertension.

This patient has successfully implemented lifestyle modifications, resulting in a significant 12-pound weight loss and a normalized blood pressure of 118/76 mmHg. For young adults who achieve their blood pressure targets through non-pharmacologic interventions, the standard of care at a 6-month evaluation is to encourage the continuation of these healthy habits and schedule an annual reassessment. Maintaining the current lifestyle reinforces positive behavior and ensures long-term cardiovascular health. Decreasing exercise frequency is counterproductive, as her current regimen is effectively managing her condition without causing symptomatic hypotension. Resuming a normal diet would likely lead to weight regain and a subsequent rise in blood pressure. Recommending weekly home blood pressure monitoring is unnecessary and may provoke anxiety, given that her blood pressure is well controlled and stable on her current lifestyle regimen.

Severe abdominal pain that radiates to the back accompanied by vomiting is a classic presentation of acute pancreatitis, which is a rare but serious adverse effect of GLP-1 agonists. Option A is the correct action; you must ensure immediate discontinuation of the medication and evaluate the patient for pancreatitis. Options C and D are incorrect because these symptoms are severe red flags, not routine gastrointestinal side effects that can be managed with reassurance, antiemetics, or dose reductions. Option B is incorrect because switching to another weight loss medication without first ruling out and treating a potentially life-threatening complication is unsafe and inappropriate.

Mild gastrointestinal symptoms like nausea are an expected side effect of GLP-1 agonists, particularly during the initiation phase. Because the patient has successfully completed the four-week initiation phase and finds the nausea tolerable, you should follow the standard titration schedule and increase the dose to the next therapeutic level (Option C). Option D is incorrect because delaying titration is only necessary if side effects are severe or intolerable. Options A and B are incorrect because the medication does not need to be discontinued or switched to an oral formulation for mild, manageable symptoms that are already resolving independently.

Due to peaking insulin resistance from placental hormones in the late third trimester, dietary management often becomes insufficient. When more than 20 to 30 percent of glucose readings exceed target values, initiating insulin therapy is the standard of care to prevent fetal macrosomia and complications. Calorie restriction for weight loss is contraindicated during pregnancy. An immediate induction at 34 weeks is premature without other acute fetal or maternal indications. Reassuring the patient ignores the significant risks of uncontrolled hyperglycemia.